Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: mixture (40), grouping (682), blend (16), amalgamation (1), recipe (32), arrangement (234)

Nivolumab-Relatlimab

Description: Chemotherapy Protocol SKIN CANCER Nivolumab in combination with Relatlimab (Opdualag) Regimen • Skin – Nivolumab in in combination with Relatlimab (Opdualag) Indication The
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-Relatlimab-Ver1.pdf

BEACON protocol v8.0 07Mar2023 signed

Description: A randomised phase IIb trial of BE AC v izumab added to Temozolomide O ± Irin tecan for children with N refractory/relapsed euroblastoma Version 8.0 dated 07-Mar-2023 Dinutuximab beta amendment Coordinating Sponsor: Sponsor Protocol Number: CAS Code: EudraCT Number: ISRCTN Reference Number: ITCC Number: Roche
Url: /Media/UHS-website-2019/Docs/PaediatricOncology/beacon-protocol-v8.0-07mar2023-signed.pdf

Ipilimumab(1mg/kg)-Nivolumab(3mg/kg)

Description: Chemotherapy Protocol RENAL CANCER IPILIMUMAB (1mg/kg)-NIVOLUMAB(3mg/kg) Regimen • Renal – Ipilimumab (1mg/kg)-Nivolumab (3mg/kg) Indi
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Ipilimumab1mgkg-Nivolumab3mgkg.pdf

Ipilimumab-Nivolumab

Description: Chemotherapy Protocol SKIN CANCER IPILIMUMAB (3mg/kg)-NIVOLUMAB (1mg/kg) Regimen • Skin – Ipilimumab (3mg/kg)-Nivolumab (1mg/kg) Indication • Ipilimum
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Ipilimumab-Nivolumab.pdf

Carboplatin(AUC6)-Paclitaxel-Pembrolizumab

Description: Chemotherapy Protocol LUNG CANCER CARBOPLATIN (AUC6)-PACLITAXEL-PEMBROLIZUMAB Regimen • Lung-Carboplatin (AUC6)-Paclitaxel-Pembrolizumab Indic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CarboplatinAUC6-Paclitaxel-Pembrolizumab.pdf

Be informed; then disclose

Description: Be informed; then disclose
Url: /HealthProfessionals/Clinical-law-updates/Be-informed-then-disclose.aspx

Ipilimumab-Nivolumab Ver1

Description: Chemotherapy Protocol MESOTHELIOMA IPILIMUMAB-NIVOLUMAB Regimen • Mesothelioma – Ipilimumab-Nivolumab Indication • Nivolumab in combination with ipilimumab is indicated for the first-line
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Mesothelioma/Ipilimumab-Nivolumab-Ver1.pdf

IPD-Dexamethasone-Isatuximab-Pomalidomide

Description: Chemotherapy Protocol Myeloma Isatuximab-Dexamethasone (40)-Pomalidomide Regimen • Myeloma – Isatuximab-Dexamethasone (40)-Po
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IPD-Dexamethasone-Isatuximab-Pomalidomide.pdf

Cisplatin-Pembrolizumab-Pemetrexed

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CISPLATIN-PEMBROLIZUMAB-PEMETREXED Regimen • NSCLC – Cisplatin-Pembrolizumab-Pemetrexed Indication • Pembrolizumab in combination with pemet
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Cisplatin-Pembrolizumab-Pemetrexed.pdf

Fulvestrant-Ribociclib

Description: Chemotherapy Protocol Breast Cancer Fulvestrant-Ribociclib Regimen • Breast Cancer – Fulvestrant-Ribociclib Indication • Fulvestrant and ri
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Fulvestrant-Ribociclib.pdf

1 to 10 of 297

Previous 1 2 3 4 5 … Next